Bank of America increased their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, March 27th.

Source: https://www.dailypolitical.com/2023/06/10/brokers-offer-predictions-for-amicus-therapeutics-inc-s-q4-2024-earnings-nasdaqfold.html

Bank of America raised their target price on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 27th.

Source: https://www.americanbankingnews.com/2023/05/01/brinker-capital-investments-llc-has-2-01-million-stock-holdings-in-amicus-therapeutics-inc-nasdaqfold.html

SkyView Investment Advisors LLC purchased a new stake in Amicus Therapeutics during the second quarter valued at $66,000.

Source: https://www.dailypolitical.com/2023/08/24/amicus-therapeutics-nasdaqfold-upgraded-to-buy-at-stocknews-com.html

This duality supports a bullish view on Amicus Therapeutics, even at its current valuation, as it indicates that the company is not merely being optimistic but is laying down a realistic path towards sustained growth and profitability.

Source: https://seekingalpha.com/article/4631070-amicus-therapeutics-uk-approval-expands-global-reach?source=feed_all_articles